IP Library Granted Patent US 7,067,260
Granted Patent B2
US 7,067,260 · App. 09/982,543 · Granted Jun 27, 2006

Methods of identifying morphogen receptor-binding analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,260
App. No.
09/982,543
Granted
Jun 27, 2006
Kind
B2
Abstract

Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptors particularly OP-1-binding cell surface receptors; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods and compositions for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods and compositions for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.

Claims (48)

1. A method for identifying a binding analog for a morphogen receptor, said morphogen sharing at least 60% amino acid sequence identity or at least 70% amino acid sequence homology with the sequence of the C-terminal 102 amino acid of SEQ ID NO: 7, and being able to substitute for OP-1 in binding to a protein comprising SEQ ID NOs. 4, 6, or 8, said binding analog having substantially the same binding affinity for said morphogen receptor as said morphogen, the method comprising:

(a) providing a sample without a Type II serine/threonine kinase morphogen receptor but containing a protein selected from:

(i) a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2);

(ii) a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3);

(iii) a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6); or

(iv) a polypeptide having binding affinity for OP-1 and encoded by a first nucleic acid capable of hybridizing under stringent conditions with a second nucleic acid comprising the sequence defined by nucleotides 256-552 of SEQ ID NO: 7 (ALK-6), the stringent conditions being hybridization in 40% formamide 5×SSPE, 5×Denhardt's Solution, 0.1% SDS at 37° C. overnight, then washing in 0.1×SSPE, 0.1% SDS at 50° C.;

(b) contacting said sample with a candidate morphogen receptor-binding analog; and

(c) detecting specific binding between said candidate morphogen receptor-binding analog and said protein;

wherein binding of said candidate morphogen receptor-binding analog to said protein is indicative that said candidate analog is a morphogen receptor-binding analog.

2. A method for identifying a binding analog of an OP-1 receptor, said analog being characterized as having substantially the same binding affinity for a cell surface receptor protein as OP-1, the method comprising:

(a) providing a cell that expresses a surface receptor protein having binding specificity for OP-1 selected from:

(i) a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2);

(ii) a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3);

(iii) a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6); or

(iv) a polypeptide having binding affinity for OP-1 and encoded by a first nucleic acid capable of hybridizing under stringent conditions with a second nucleic acid comprising the sequence defined by nucleotides 256-552 of SEQ ID NO: 7 (ALK-6), the stringent conditions being hybridization in 40% formamide 5×SSPE, 5×Denhardt's Solution, 0.1% SDS at 37° C. overnight, then washing in 0.1×SSPE, 0.1% SDS at 50° C.;

(b) contacting said cell with a candidate OP-1 receptor-binding analog; and

(c) detecting induction of an OP-1-mediated cellular response;

wherein detection of induction of said OP-1-mediated cellular response is indicative that said candidate analog is an OP-1 receptor-binding analog.

3. The method of claim 2 wherein said OP-1 mediated cellular response detected in step (c) is induction of threonine or serine-specific phosphorylation, inhibition of epithelial cell growth, or induction of a cell differentiation marker.

4. The method of claim 2 or 3 wherein said cell comprises a transfected nucleic acid comprising a reporter gene in operative association with a control element derived from an OP-1 inducible protein, and wherein the activity of said reporter gene can be detected as said OP-1-mediated cellular response upon stimulation by OP-1 or analog thereof in said cell.

5. The method of claim 2 or 3 , wherein said surface receptor protein further comprises part or all of a Type II serine/threonine kinase receptor protein having binding affinity for OP-1, activin or BMP-4.

6. A kit for identifying OP-1 or a candidate OP-1 receptor binding analog in a sample, the kit comprising:

(a) a receptacle adapted to receive said sample, said receptacle containing a protein selected from:

(i) a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2);

(ii) a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3);

(iii) a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6); or

(iv) a polypeptide having binding affinity for OP-1 and encoded by a first nucleic acid capable of hybridizing under stringent conditions with a second nucleic acid comprising the sequence defined by nucleotides 256-552 of SEQ ID NO: 7 (ALK-6), the stringent conditions being hybridization in 40% formamide 5×SSPE, 5×Denhardt's Solution, 0.1% SDS at 37° C. overnight, then washing in 0.1×SSPE, 0.1% SDS at 50° C.; and

(b) means for detecting induction of an OP-1-mediated cellular response as a means for detecting interaction of OP-1 or a candidate OP-1 receptor-binding analog with said protein of part (a), said OP-1 or candidate analog comprising part of said sample provided to said receptacle.

7. The kit of claim 6 , further comprising a serine/threonine Type II receptor having binding specificity for OP-1, activin or BMP-4.

8. The method of claim 1 , wherein said morphogen is OP-1.

9. The method of claim 1 , wherein said morphogen is 60A, DPP, OP-2, OP-3, BMP-2, BMP-4, BMP-5, BMP-6, Vg1, GDF-1, or Vgr-1.

10. The method of claim 4 , wherein said surface receptor protein further comprises part or all of a Type II serine/threonine kinase receptor protein having binding affinity for OP-1, activin or BMP-4.

11. A kit for identifying a binding analog for a morphogen receptor in a sample, said morphogen being characterized as sharing at least 60% amino acid sequence identity or at least 70% amino acid sequence homology with the sequence of the C-terminal 102 amino acids of SEQ ID NO: 7, and being able to substitute for OP-1 in binding to a protein comprising SEQ ID NOs. 4, 6, or 8, the kit comprising:

(a) a receptacle adapted to receive said sample, said receptacle does not contain a Type II serine/threonine kinase morphogen receptor but contains protein selected from:

(i) a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2);

(ii) a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3);

(iii) a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6); or

(iv) a polypeptide having binding affinity for OP-1 and encoded by a first nucleic acid capable of hybridizing under stringent conditions with a second nucleic acid comprising the sequence defined by nucleotides 256-552 of SEQ ID NO: 7 (ALK-6), the stringent conditions being hybridization in 40% formamide 5×SSPE, 5×Denhardt's Solution, 0.1% SDS at 37° C. overnight, then washing in 0.1×SSPE, 0.1% SDS at 50° C.; and

(b) means for detecting specific binding interaction of OP-1 or said candidate analog with said protein of part (a), said OP-1 or candidate analog comprising part of said sample provided to said receptacle.

12. The method of claim 1 , wherein said protein is a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2).

13. The method of claim 1 , wherein said protein is a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3).

14. The method of claim 1 , wherein said protein is a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6).

15. The method of claim 2 , wherein said surface receptor protein is a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2).

16. The method of claim 2 , wherein said surface receptor protein is a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3).

17. The method of claim 2 , wherein said surface receptor protein is a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6).

18. The kit of claim 6 or claim 11 , wherein said protein is a polypeptide comprising an amino acid sequence defined by residues 16-123 of SEQ ID NO: 4 (ALK-2).

19. The kit of claim 6 or claim 11 , wherein said protein is a polypeptide comprising an amino acid sequence defined by residues 24-152 of SEQ ID NO: 6 (ALK-3).

20. The kit of claim 6 or claim 11 , wherein said protein is a polypeptide comprising an amino acid sequence defined by residues 23-122 of SEQ ID NO: 8 (ALK-6).

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2016
From: STRYKER CORPORATION
To: MARIEL THERAPEUTICS, INC.
Reel/Frame 037460/0806 →
LIEN Recorded Jan 8, 2016
From: STRYKER CORPORATION
To: MARIEL THERAPEUTICS, INC.
Reel/Frame 037461/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2014
From: STRYKER CORPORATION
To: MARIEL THERAPEUTICS, INC.
Reel/Frame 033535/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2008
From: CURIS, INC.
To: STRYKER CORPORATION
Reel/Frame 021489/0045 →
MERGER Recorded Jul 16, 2003
From: CREATIVE BIOMOLECULES, INC.; ONTOGENY, INC.; REPROGENESIS, INC.
To: CURIS, INC.
Reel/Frame 013798/0552 →